In 1973-4 nearly 10 000 Montreal drivers, interviewed by telephone, provided information about medical and associated factors and about driving habits, in particular annual mileage. Records of accidents suffered by these drivers in the Province of Quebec over 39 months (1973-6) were also collected. The 7634 current drivers, with appropriate permits, and all of whose data passed reliability edits, were placed into nine sets-that is, three classes: women; men with the usual permit; and men with a chauffeur's permit to drive taxis, heavy vehicles, etc; further subdivided into three age groups. Accident rates depended on mileage, but after allowance for differences in mileage, accident rates still varied with sex, type of permit, and age. No association of the risk of accidents and a medical or related factor was consistent over all nine sets of drivers. Of the 7634 drivers, 347 had had at least one accident causing injury or death in the 39 months from 1 January 1973. These "cases" were compared with 347 "referents," closely matched for sex, type of permit, age, and reported mileage, but without accident causing injury or death. Cases included higher proportion who worked irregular shifts, who were overweight, and who reported smoking while driving. Relative to the chance of a referent suffering any accident in the 39-month period, a case had at least double the risk of having an accident in addition to the index accident.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1052913 | PMC |
http://dx.doi.org/10.1136/jech.36.2.140 | DOI Listing |
Alzheimers Dement
December 2024
Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands.
Background: There is a strong link between tau and progression of Alzheimer's disease (AD), necessitating an understanding of tau spreading mechanisms. Prior research, predominantly in typical AD, suggested that tau propagates from epicenters (regions with earliest tau) to functionally connected regions. However, given the constrained spatial heterogeneity of tau in typical AD, validating this connectivity-based tau spreading model in AD variants with distinct tau deposition patterns is crucial.
View Article and Find Full Text PDFBackground: For individuals on the Alzheimer's disease trajectory, amyloid positivity generally precedes tau positivity, as defined by PET biomarkers. However, multiple studies report amyloid-negative tau-positive PET (A-T+) participants, whose clinical implications remain unclear. Here, utilizing the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, we examined how A-T+ participants differ from other A/T profiles based on cognition, fluid biomarkers, and neuropathology-we also investigated the longitudinal trajectories of A-T+ participants.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Lund University, Clinical Memory Research Unit, Lund, Sweden.
Background: There is a strong link between tau and progression of Alzheimer's disease (AD), necessitating an understanding of tau spreading mechanisms. Prior research, predominantly in typical AD, suggested that tau propagates from epicenters (regions with earliest tau) to functionally connected regions. However, given the constrained spatial heterogeneity of tau in typical AD, validating this connectivity-based tau spreading model in AD variants with distinct tau deposition patterns is crucial.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: Mivelsiran (ALN-APP) is an investigational, intrathecally administered RNA interference therapeutic designed to lower levels of amyloid-β (Aβ) peptide, a key driver of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) pathogenesis, by reducing upstream production of amyloid precursor protein (APP). We report additional safety, pharmacodynamic, and biomarker data from the double-blind, placebo-controlled, single ascending dose part of the ongoing mivelsiran Phase 1 study (NCT05231785).
Method: Patients with early-onset AD (symptom onset <65 years of age, Clinical Dementia Rating global score 0.
Background: Gut microbiota modulation of the brain function may present an opportunity to devise preventive or treatment strategies to manage impairments such as cognitive frailty (CF). This study aims to uncover the relationship between CF, gut microbiota, intestinal permeability and proteome.
Method: A total of 137 fecal samples of the elderly were collected, and subjected to DNA analysis, and enzyme-linked immunosorbent assays (ELISA).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!